ipilimumab,nivolumab
bms
['niche-2']
exciting results from the niche-2 trial investigating the use of neoadjuvant immunotherapy in dmmr colon cancer 
Medical Oncology Trainee NI. HSC R&D Research Fellow @CPH_QUB. Views and opinions my own.